Delivery Order SPE2DB22D1202-SPE2DB24FUPV4

Award Date 2/6/24
Potential Completion Date 2/7/24
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,979.81 firm fixed-price delivery order covers the procurement of 4 mg Glimepiride tablets, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of December 5, 2024 and was awarded on December 4, 2020. This award is associated with Amerisourcebergen's $999,999,999 Indefinite...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,734.33 firm fixed-price delivery order is for the supply of GLIMEPIRIDE 4 MG TABLET 100S, a medication used to treat diabetes. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,529.84 fixed-price delivery order is for the supply of 4 mg glimepiride tablets, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of February 21, 2025 and was awarded on February 20, 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,456.72 firm fixed-price delivery order is for the supply of 4 mg Glimepiride tablets, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of November 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,349.68 firm fixed-price delivery order is for the supply of 4 mg glimepiride tablets, a medication used to treat diabetes. The contract has a completion date of July 26, 2024 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite...
This federal contract award, valued at $1,281.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Glimepiride 2 mg tablets, a medication used to treat type 2 diabetes. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,690.42 firm fixed-price delivery order covers the supply of 4 mg Glimepiride tablets, a medication used to treat diabetes. The contract has an ultimate completion date of December 23, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,316.81 firm fixed-price delivery order is for the supply of 4 mg glimepiride tablets, a medication used to treat type 2 diabetes. The award has an ultimate completion date of December 30, 2024 and was made on December 27, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
This federal contract award, valued at $5,760.71, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Glimepiride 4 mg tablets, a medication used to treat type 2 diabetes. The contract is a Firm Fixed Price Delivery Order with a completion date of November 8, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,330.04 firm fixed price delivery order is for the supply of 4 mg Glimepiride tablets, a medication used to treat diabetes. The contract has an ultimate completion date of October 28, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB24FUPV4
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,386.08 firm-fixed-price delivery order is for the supply of 4 mg glimepiride tablets, a medication used to treat diabetes. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This IDC, which runs through November 2026, enables efficient government procurement of essential medical commodities across multiple therapeutic areas. The contract award was not designated as a set-aside.

Generated 5/14/25, 10:06 AM